2024
Pathophysiology of Cystic Fibrosis Liver Disease
Kasper V, Assis D. Pathophysiology of Cystic Fibrosis Liver Disease. Pediatric Pulmonology 2024, 59: s98-s106. PMID: 39105342, DOI: 10.1002/ppul.26869.Peer-Reviewed Original ResearchConceptsComplication of cystic fibrosisCF liver diseaseHeterogeneity of clinical manifestationsManifestations of CFDisease-modifying factorsCFTR mutationsHepatobiliary complicationsBiliary stricturesBiliary cholestasisClinical manifestationsCystic fibrosisLiver diseaseTherapeutic approachesCF careDisease modelsDisease
2023
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations
Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M, Cipolli M, Debray D, Green N, Hughan K, Hunt W, Leey J, Ling S, Morelli G, Peckham D, Pettit R, Philbrick A, Stoll J, Vavrina K, Allen S, Goodwin T, Hempstead S, Narkewicz M. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology 2023, 79: 1220-1238. PMID: 37934656, PMCID: PMC11020118, DOI: 10.1097/hep.0000000000000646.Peer-Reviewed Original ResearchConceptsAdvanced liver diseaseCystic fibrosisLiver diseaseHepatobiliary involvementHepatobiliary complicationsCF-associated liver diseasePubMed literature searchCystic fibrosis screeningScreening ultrasoundPortal hypertensionOutcome questionsLiver biopsyLiver failureMultilobular cirrhosisFibrosis screeningConsensus recommendationsFull-text reviewHepatobiliary diseaseCF FoundationLiterature searchThirty-oneCF outcomesMultidisciplinary committeeDiseaseComplicationsWED-283 Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD)
Dean R, Yazdanfar M, Zepeda J, Levy C, Gordon S, Forman L, Lammert C, Assis D, Pratt D, Gungabissoon U, McGirr A, Mukherjee S, McLaughlin M, Bowlus C. WED-283 Investigating the cholestatic pruritus of primary sclerosing cholangitis (ItCh-PSC): a study of patients participating in the consortium for autoimmune liver disease (CALiD). Journal Of Hepatology 2023, 78: s388. DOI: 10.1016/s0168-8278(23)01040-1.Peer-Reviewed Original ResearchRecent Advances in the Management of Primary Sclerosing Cholangitis
Assis D, Bowlus C. Recent Advances in the Management of Primary Sclerosing Cholangitis. Clinical Gastroenterology And Hepatology 2023, 21: 2065-2075. PMID: 37084929, DOI: 10.1016/j.cgh.2023.04.004.Peer-Reviewed Original ResearchConceptsChronic cholestatic liver diseasePrimary sclerosing cholangitisInflammatory bowel diseasePrognostication of patientsCholestatic liver diseaseSclerosing cholangitisBowel diseaseLiver failureClinical featuresLiver diseaseMedical managementBiliary treeComplex pathophysiologyEffective therapyPharmacologic agentsRare natureCurrent conceptsDiseaseCholangitisFurther studiesCholangiocarcinomaPatientsPathophysiologyTherapyPrognostication
2021
Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine
Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.Peer-Reviewed Original ResearchConceptsHuman cholestatic diseasesCholestatic diseaseBiliary organoidsStudy of pathophysiologyCholestasis ResearchBiliary treeDisease stageIndividual patientsTranslational studiesPrimary cholangiocytesPersonalized approachBiliary tissueApplication of organoidsStandardization of terminologyTranslational medicineDiseaseOrganoidsMedicineOrganoid technologyPatientsPathophysiology
2020
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases
Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020, 72: 671-722. PMID: 31863477, DOI: 10.1002/hep.31065.Peer-Reviewed Original Research
2019
The Contribution of B Cells in Autoimmune Liver Diseases
Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Seminars In Liver Disease 2019, 39: 422-431. PMID: 31226726, PMCID: PMC6800599, DOI: 10.1055/s-0039-1688751.BooksConceptsAutoimmune liver diseaseT cell activationB cellsLiver diseaseT cellsCell activationB-cell mechanismsRegulatory T cellsProduction of autoantibodiesAutoreactive T cellsAutoreactive B cellsGeneration of cytokinesAutoimmune hepatitisCell mechanismsAntigen presentationDisease pathogenesisAutoantibodiesDiseaseCellsActivationVast majorityHepatitisCholangiopathyAutoimmunityCytokines
2018
Chronic Complications of Cholestasis Evaluation and Management
Assis DN. Chronic Complications of Cholestasis Evaluation and Management. Clinics In Liver Disease 2018, 22: 533-544. PMID: 30259851, DOI: 10.1016/j.cld.2018.03.014.BooksMeSH KeywordsAbsorptiometry, PhotonAvitaminosisBone Density Conservation AgentsBone Diseases, MetabolicCarcinoma, HepatocellularCholestasisDiet, HealthyEarly Detection of CancerEsophageal and Gastric VaricesExerciseFibric AcidsGastrointestinal HemorrhageHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasHypertension, PortalLiver Cirrhosis, BiliaryLiver NeoplasmsMass ScreeningOsteoporosisOsteoporotic FracturesVitamin A DeficiencyVitamin D DeficiencyVitamin E DeficiencyVitamin K DeficiencyConceptsPrimary biliary cholangitisChronic cholestasisFat-soluble vitamin deficiencyEarly-stage diseaseMetabolic bone diseaseCardiovascular eventsChronic complicationsPortal hypertensionBiliary cholangitisVitamin deficiencyBone diseaseLong-term effectsNotable riskCholestasisComplicationsPatientsPractical managementDiseaseRiskHarmful consequencesCholangitisHypertensionHyperlipidemiaOsteoporosisTherapy
2017
Gallbladder and bile duct disease in Cystic Fibrosis
Assis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis. Journal Of Cystic Fibrosis 2017, 16: s62-s69. PMID: 28986023, DOI: 10.1016/j.jcf.2017.07.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBile duct diseaseCystic fibrosisHigh-quality careDuct diseaseExtra-pulmonary manifestationsBile duct pathologyEfficient clinical evaluationHepatobiliary disturbancesCommon complicationClinical presentationBiliary diseaseDuct pathologyBiliary treeClinical evaluationBiliary disordersUndetected pathologyGallbladderDiverse disordersPatientsDiseaseCareFibrosisPathologyDisordersComplicationsFRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease
Roberts S, Leng L, Soroka C, Boyer J, Bucala R, Assis D. FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. Journal Of Hepatology 2017, 66: s363-s364. DOI: 10.1016/s0168-8278(17)31067-x.Peer-Reviewed Original Research
2010
Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient.
Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterology 2010, 56: 331-43. PMID: 21037549.Peer-Reviewed Original ResearchConceptsPost-transplant periodLiver diseaseAdvanced liver diseaseManagement of coagulopathyAcute liver failureManagement of thrombocytopeniaImportant clinical skillSuperimposed complicationsHepatic dysfunctionTransplant patientsLiver failureCoagulation changesTransplant periodPathophysiologic changesBlood productsCoagulation testingCoagulopathyThrombocytopeniaPatientsClinical skillsDiseasePreSepsisComplicationsDysfunction